pam50 signatures Search Results


chi-square test  (CH Instruments)
90
CH Instruments chi-square test
Association of exoSIG risk score with characteristics of breast cancer patients. (A & B) Univariate and multivariate cox hazard ratio (HR) distributions of exoSIG risk scores versus seven clinical characteristics. (C) Risk grouping based on exoSIG risk scores. Up-panel: correlation between risk grouping and risk score; Middle-panel: correlation between survival status and survival time; Low-panel: Heatmap of expression patterns of 10 exoMols in risk patients. (D) Distribution of different clinical characteristics in the low-risk and high-risk patients. (E) Correlation of clinical characteristics of breast cancer patients with exoSIG risk scores. Breast cancer patients with ER-, PR-, high stage, high age, <t>PAM50-LumB,</t> and PAM50-Basal subtype had higher exoSIG risk scores.
Chi Square Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pam50+signatures/pmc10232662-82-45-48?v=CH+Instruments
Average 90 stars, based on 1 article reviews
chi-square test - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
pam50 gene expression signature  (Bioclassifier LLC)
90
Bioclassifier LLC pam50 gene expression signature
Patient characteristics
Pam50 Gene Expression Signature, supplied by Bioclassifier LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pam50+signatures/pmc06491406-284-8-16?v=Bioclassifier+LLC
Average 90 stars, based on 1 article reviews
pam50 gene expression signature - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
pam50  (ARUP Laboratories)
90
ARUP Laboratories pam50
Patient characteristics
Pam50, supplied by ARUP Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pam50+signatures/pm22987965-56-4-11?v=ARUP+Laboratories
Average 90 stars, based on 1 article reviews
pam50 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Association of exoSIG risk score with characteristics of breast cancer patients. (A & B) Univariate and multivariate cox hazard ratio (HR) distributions of exoSIG risk scores versus seven clinical characteristics. (C) Risk grouping based on exoSIG risk scores. Up-panel: correlation between risk grouping and risk score; Middle-panel: correlation between survival status and survival time; Low-panel: Heatmap of expression patterns of 10 exoMols in risk patients. (D) Distribution of different clinical characteristics in the low-risk and high-risk patients. (E) Correlation of clinical characteristics of breast cancer patients with exoSIG risk scores. Breast cancer patients with ER-, PR-, high stage, high age, PAM50-LumB, and PAM50-Basal subtype had higher exoSIG risk scores.

Journal: Computational and Structural Biotechnology Journal

Article Title: A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity

doi: 10.1016/j.csbj.2023.05.013

Figure Lengend Snippet: Association of exoSIG risk score with characteristics of breast cancer patients. (A & B) Univariate and multivariate cox hazard ratio (HR) distributions of exoSIG risk scores versus seven clinical characteristics. (C) Risk grouping based on exoSIG risk scores. Up-panel: correlation between risk grouping and risk score; Middle-panel: correlation between survival status and survival time; Low-panel: Heatmap of expression patterns of 10 exoMols in risk patients. (D) Distribution of different clinical characteristics in the low-risk and high-risk patients. (E) Correlation of clinical characteristics of breast cancer patients with exoSIG risk scores. Breast cancer patients with ER-, PR-, high stage, high age, PAM50-LumB, and PAM50-Basal subtype had higher exoSIG risk scores.

Article Snippet: Clinical survival features of high-risk patients were worse than those of low-risk patients, such as estrogen-receptor (ER) status (Chi-square test, P < 0.001), progesterone-receptor (PR) status (Chi-square test, P < 0.001), node coded (Chi-square test, P < 0.05), AJCC stage (Chi-square test, P < 0.001), 50-gene signature (PAM50) (Chi-square test, P < 0.001) and age (Student T test, P < 0.01) ( C).

Techniques: Expressing

Patient characteristics

Journal: Breast Cancer Research and Treatment

Article Title: Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

doi: 10.1007/s10549-018-05097-5

Figure Lengend Snippet: Patient characteristics

Article Snippet: Philip S. Bernard is an inventor of the PAM50 gene expression signature and a stakeholder in BioClassifier LLC, a company that licensed the PAM50 know-how to Nanostring Inc for the commercialization of Prosigna.

Techniques: